• IM/Endocrinology

• Pituitary

The research of Odelia B. Cooper, MD, focuses on pituitary tumors, with the goal of understanding signaling pathways contributing to pituitary tumorigenesis in order to develop new therapies targeting recurrent tumor growth and invasion. Based on her work on a rare subset of aggressive tumors, Cooper began to investigate mechanisms by which pituitary tumors progress from noninvasive to invasive behavior. This led to her interest in the ErbB pathway to see if these receptors play an active role in pituitary tumorigenesis. Cooper showed the clinical response of patients with aggressive tumors to ErbB targeted therapy.

• Undergraduate: Johns Hopkins University, 1998
• Medical School: Johns Hopkins University School of Medicine, 2002
• Residency: Cedars-Sinai, 2006
• Fellowship: Cedars-Sinai, 2008
• Fellowship: Cedars-Sinai, 2009

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Endocrinology
• Fatty Liver Program
• Hypertension Center
• Department of Neurology and Neurosurgery
• Diabetes Center
• Department of Medicine
• Pituitary Center
• Thyroid Cancer Program
• Cancer
• Medicine
• Adrenal Program
• Thyroid and Parathyroid Disorders

• R21 Grant, National Institute of Diabetes and Digestive and Kidney Diseases
• Outstanding PBL Tutor Award, UCLA
• Member, Endocrine Society and Pituitary Society
• K23 Career Development Award, National Institutes of Health

• Schell MJ, Cooper OB, Snyder SH. D-aspartate localizations imply neuronal and neuroendocrine roles. Proc Natl Acad Sci USA. 1997;(5):2013-2018.
• Cooper O, Geller JL, Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab. 2008;(4):234-238.
• Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, Melmed S. Heregulin regulates prolactinoma gene expression. Cancer Res. 2009;(10):4209-4216.